MINNEAPOLIS, Nov. 28, 2011 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX) is the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective results. Urologix provides urologist customers two proven technologies to treat the widest range of patients suffering from enlarged prostate in the comfort of their office setting, Cooled ThermoTherapy™ (CTT) and Prostiva® RF Therapy. Today, the Company announced it will present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference on Tuesday, December 6, 2011 at 2:20 p.m. PST. The event will be held at the St. Regis Hotel in San Francisco, CA.
Stryker Warren, Chief Executive Officer, will provide an overview of the Company, current business strategies and growth prospects.
A live audio webcast of the presentation will be available via the "Investors" page of the Urologix website, www.urologix.com. Please log on through Urologix's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website following the presentation.
About Urologix
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families. The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
The Urologix, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7867